Results 1 to 10 of about 5,684 (155)

Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy [PDF]

ESC Heart Failure
Aims Tafamidis improves clinical outcomes in transthyretin amyloid cardiomyopathy (ATTR‐CM), yet how tafamidis affects cardiac structure and function remains poorly described.
Benedikt Bernhard, Stephan Dobner, Giancarlo Spanò   +2 more
exaly   +5 more sources

Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy

ESC Heart Failure, 2023
Aims Tafamidis improves prognosis in patients with transthyretin amyloid cardiomyopathy (ATTR‐CM). However, real‐world data on the therapeutic effect of tafamidis are lacking.
Kei Morikawa, Mami Morioka, Fumi Oike
exaly   +2 more sources

Functional Stability Measured by Changes in the 6-min Walk Test in Patients Treated with Tafamidis Versus Placebo: Post hoc Analysis from ATTR-ACT [PDF]

Cardiology and Therapy
Introduction Tafamidis, a transthyretin stabilizer for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), significantly reduced the decline in 6-min walk test (6MWT) distance, a marker of functional stability, compared with placebo in the ...
Ronald Witteles, Mazen A. Hanna, Martha Grogan, Perry Elliott, Ronnie Wang, Pablo Garcia-Pavia   +5 more
doaj   +2 more sources

Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension [PDF]

Cardiology and Therapy
Introduction Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are at high risk of cardiovascular (CV)-related hospitalizations (CVH), which are associated with higher mortality.
Thibaud Damy, Ronald Witteles, Francesco Cappelli, Ronnie Wang, Martha Grogan   +4 more
doaj   +2 more sources

A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study [PDF]

Journal of Comparative Effectiveness Research
Aim: Tafamidis and acoramidis are transthyretin stabilizers approved for the treatment of transthyretin amyloid cardiomyopathy. We compared the effectiveness of acoramidis versus tafamidis regarding allcause mortality (ACM).
Philippe Debonnaire, Peter-Paul Zwetsloot, Roman Pfister, Pau Llàcer, Alberto Cipriani, Paolo Milani, Diana Bonderman, Christoph Ohlmeier, Thomas Evers, Richard Wyss, Elisabetta Patorno, Riddhi Doshi, Julien Beisel, Craig I Coleman, Carlos Aguiar, Tomas Ripoll-Vera   +15 more
doaj   +2 more sources

Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT [PDF]

Cardiology and Therapy
Introduction Tafamidis is approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM) on the basis of results of the phase 3 study ATTR-ACT. This post hoc analysis from ATTR-ACT evaluated the effect of tafamidis on transthyretin (TTR) concentration ...
Mathew S. Maurer, Perry Elliott, Jeffery W. Kelly, Mazen Hanna, Evan T. Powers, Steve Riley, Rong Wang, Pablo Garcia-Pavia   +7 more
doaj   +2 more sources

Mortality in octogenarian patients with transthyretin amyloidosis treated with tafamidis: a systematic review and meta-analysis [PDF]

Orphanet Journal of Rare Diseases
Background Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects older adults, and tafamidis has proven efficacy in reducing mortality and hospitalizations in this population.
Christiane Santo, Vinicius Machado Correia, Maria L. R. Defante, Bruno Ferlin Saccomani Barbosa, Andre Dabarian, Bruno Vaz Kerges Bueno, Vagner Madrini Junior, Fabio Fernandes   +7 more
doaj   +2 more sources

Neurologic Stability During Tafamidis Treatment in Transthyretin Amyloidosis with a Mixed Phenotype: A Multicenter Real-World Study [PDF]

Cardiology and Therapy
Introduction Real-world evidence on the effect of tafamidis in mixed-phenotype transthyretin (TTR) amyloidosis (ATTR amyloidosis) is limited. This study assessed changes in neurologic and other measures in patients with mixed-phenotype ATTR amyloidosis ...
Nowell M. Fine, Nicholas S. Streicher, Isabel Conceição, João Agostinho, Laura Obici, Giovanni Palladini, Martin Carlsson, Leslie Amass, Farooq H. Sheikh   +8 more
doaj   +2 more sources

One-year worsening heart failure and myocardial T1 mapping in patients with wild-type transthyretin amyloid cardiomyopathy undergoing tafamidis treatment [PDF]

International Journal of Cardiology: Heart & Vasculature
Background: There is a paucity of data regarding short-term outcomes and treatment responsiveness of myocardial T1 mapping via cardiac magnetic resonance (CMR) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) undergoing tafamidis therapy ...
Toshiro Kitagawa, Kotaro Hamamoto, Daiki Okamoto, Yuki Ikegami, Yoshiharu Sada, Fuminari Tatsugami, Yukiko Nakano   +6 more
doaj   +2 more sources

Survival in a Contemporary, Real-World, Matched Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated vs Not Treated with Tafamidis [PDF]

Cardiology and Therapy
Introduction Tafamidis is approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) and has shown a survival benefit in the phase 3 study ATTR-ACT and in real-world settings.
Fabian aus dem Siepen, Angela Dispenzieri, Mazen Hanna, Martin Carlsson, Pablo Garcia-Pavia   +4 more
doaj   +2 more sources